Translating IL-6 biology into effective treatments.
Nat Rev Rheumatol
; 16(6): 335-345, 2020 06.
Article
in English
| MEDLINE | ID: covidwho-2313712
ABSTRACT
In 1973, IL-6 was identified as a soluble factor that is secreted by T cells and is important for antibody production by B cells. Since its discovery more than 40 years ago, the IL-6 pathway has emerged as a pivotal pathway involved in immune regulation in health and dysregulation in many diseases. Targeting of the IL-6 pathway has led to innovative therapeutic approaches for various rheumatic diseases, such as rheumatoid arthritis, juvenile idiopathic arthritis, adult-onset Still's disease, giant cell arteritis and Takayasu arteritis, as well as other conditions such as Castleman disease and cytokine release syndrome. Targeting this pathway has also identified avenues for potential expansion into several other indications, such as uveitis, neuromyelitis optica and, most recently, COVID-19 pneumonia. To mark the tenth anniversary of anti-IL-6 receptor therapy worldwide, we discuss the history of research into IL-6 biology and the development of therapies that target IL-6 signalling, including the successes and challenges and with an emphasis on rheumatic diseases.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Biological Factors
/
Rheumatic Diseases
/
Interleukin-6
/
Coronavirus Infections
/
Betacoronavirus
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Nat Rev Rheumatol
Journal subject:
Rheumatology
Year:
2020
Document Type:
Article
Affiliation country:
S41584-020-0419-z
Similar
MEDLINE
...
LILACS
LIS